162 related articles for article (PubMed ID: 16322338)
1. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Endocr Relat Cancer; 2005 Dec; 12(4):999-1009. PubMed ID: 16322338
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
[TBL] [Abstract][Full Text] [Related]
3. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Eur J Cancer; 2005 Aug; 41(12):1824-30. PubMed ID: 16051478
[TBL] [Abstract][Full Text] [Related]
4. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Buchholz S; Keller G; Schally AV; Halmos G; Hohla F; Heinrich E; Koester F; Baker B; Engel JB
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10403-10407. PubMed ID: 16801542
[TBL] [Abstract][Full Text] [Related]
5. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
[TBL] [Abstract][Full Text] [Related]
6. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Szepeshazi K; Schally AV; Nagy A; Halmos G
Pancreas; 2005 Oct; 31(3):275-82. PubMed ID: 16163060
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
Stangelberger A; Schally AV; Letsch M; Szepeshazi K; Nagy A; Halmos G; Kanashiro CA; Corey E; Vessella R
Int J Cancer; 2006 Jan; 118(1):222-9. PubMed ID: 16003723
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
10. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
Plonowski A; Nagy A; Schally AV; Sun B; Groot K; Halmos G
Int J Cancer; 2000 Nov; 88(4):652-7. PubMed ID: 11058885
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
Sotomayor S; Muñoz-Moreno L; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Cancer; 2010 Oct; 127(8):1813-22. PubMed ID: 20099275
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
Szereday Z; Schally AV; Nagy A; Plonowski A; Bajo AM; Halmos G; Szepeshazi K; Groot K
Br J Cancer; 2002 Apr; 86(8):1322-7. PubMed ID: 11953892
[TBL] [Abstract][Full Text] [Related]
13. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
14. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
15. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Hohla F; Schally AV; Kanashiro CA; Buchholz S; Baker B; Kannadka C; Moder A; Aigner E; Datz C; Halmos G
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18671-6. PubMed ID: 18003891
[TBL] [Abstract][Full Text] [Related]
17. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
18. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
19. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
